Regeneron's Inmazeb became the first FDA-approved Ebola virus treatment drug.

The Ebola virus belongs to the silk virus family and can cause Ebola haemorrhagic fever, which can cause death and contains several different degrees of symptoms (including nausea, vomiting, diarrhea, skin color changes, systemic soreness, internal bleeding, in vitro haemorrhage, fever, etc.), and the symptoms of the infected person are very similar to the Marburg virus of the same silk virus.
The U.S. Food and Drug Administration (FDA) announced Wednesday that it has approved Regeneron Pharmaceuticals' three-antibody mixture Inmazeb (atoltivimab / maftivimab / odesivimab-ebgn) for the treatment of Ebola virus infection.
the three monoclonal antibodies that make up Inmazeb bind to different tables on the zairian Ebola virus glycoprotein, preventing them from attaching and entering the host cells, according to the agency.
the FDA evaluated Inmazeb in its priority review.
approval was supported by PALM trial data, which showed inmazeb was superior to Map Biopharmaceuticals' ZMapp and Gilead's Remdesivir in reducing mortality from Ebola virus infection.
same time, detailed PALM results released on NEJM showed inmazeb outperforming ZMapp on several metrics.
the main endpoint of the 28-day mortality rate, 33.5 percent of those who received Inmazeb died, up from 51.3 percent in ZMapp.
.